UNLOCKING CURES WITH INNOVATIVE R&D
At TM3 Therapeutics, we believe that the ability to reduce the impact of an infectious disease or cancer lies within the etiologic agent itself. To create a powerful immunogen, a thorough understanding of the immune response against an attack by the etiologic agent is necessary. We can confidently state that our track record of successful R&D in vaccine development demonstrate our thorough understanding of this field.
TM3 Therapeutics has developed proprietary technology to create fully inactivated, whole agent vaccines. These vaccines have been proven to elicit comparable immune responses to some live-attenuated vaccines, and much more superior to many commercial “dead” inactivated vaccines.
We have developed patented platform technology for the development of therapeutic vaccines against cancers.
We have developed a novel method for In Vitro generation of fully human monoclonal antibodies against virtually unlimited antigens.
TM3 Therapeutics founders have over 20 years of Research and Development (R&D) experience.
• We have led a Phase I Clinical Trial in cardiovascular R&D and several GLP pre-clinical trials in rabbits,
mice, and non-human primate animal models for atherosclerosis.
• We have led several GLP pre-clinical trials for therapeutic HIV vaccine development using non-human
primates and mice.
• We have led pre-clinical R&D for the development of prophylactic vaccines against corona viruses,
flavi viruses, arteri viruses, rhinoviruses, paramyxo viruses, and arbo viruses.
CURRENT R&D EFFORTS AT TM3
At TM3, we are engaged in R&D of several Vaccines targeting human and animal health diseases. One such vaccine is a cocktail vaccine that will encompass the major etiologic agents responsible for the annual flu season. We are also performing R&D on several etiologic agents targeting human and animal health.
TM3 also offers pre-clinical contract Research Services to small and large biotechnology and pharmaceutical companies. We invite you to explore the R&D and Services offered by TM3.